A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose (20 mg/Day), 3-Month, Multicenter Study of the Energy Intake Effects and Safety of SR141716 [rimonabant] With or Without Hypocaloric Diet in Obese Patients.

Trial Profile

A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose (20 mg/Day), 3-Month, Multicenter Study of the Energy Intake Effects and Safety of SR141716 [rimonabant] With or Without Hypocaloric Diet in Obese Patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Jul 2009

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Acronyms REBA
  • Sponsors Sanofi
  • Most Recent Events

    • 12 May 2009 Actual patient number (156) added as reported by ClinicalTrials.gov.
    • 12 May 2009 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
    • 05 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top